ARVO 2023: Enzyme Replacement Treatment May Slow Retinal Thinning With CLN2-Type Batten Disease
Safety, effectiveness shown in first intravitreal enzyme replacement research in humans
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.